AbbVie Announced Topline Results From Phase 3 SEQUENCE Trial Of Skyrizi (Risankizumab) Versus Stelara (Ustekinumab); The Study Met Its Primary Endpoint In Patients With Moderately To Severely Active Crohn’s Disease Who Have Failed One Or More Anti-TNFs.